Dermapharm Holding SE (DMP) AI Stock Analysis

• Market Cap: €1.90B
• Dividend Yield: 2.56%
• Average Volume (3M): 25.50K
• Price to Earnings (P/E): 18.3
• Beta (1Y): 0.51
• Revenue Growth: 6.24%
• EPS Growth: 83.05%
• Country: DE
• Employees: 3,610
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.62
• Shares Outstanding: 53,840,000
• 10 Day Avg. Volume: 24,273
• 30 Day Avg. Volume: 25,500
• PEG Ratio: 0.64
• Price to Book (P/B): 3.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 13.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €44.67
• Price Target Upside: 26.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 70 Outperform
• Price Target: €39.00 ▲(10.80%Upside)

Dermapharm Holding SE is in a strong financial position with consistent revenue growth and solid cash flow generation. Technical indicators suggest a neutral market position, while valuation metrics point to fair market pricing. The absence of significant earnings call data and corporate events limits additional insights.

Positive Factors

Earnings

Dermapharm Holding reported a better-than-expected end to the year with a 7% earnings and 4% sales beat in the fourth quarter.

Financial Performance

The adjusted EBITDA for the fiscal year exceeded expectations, supported by Montavit.

International Market Growth

Ex-vac, revenues in BP grew by +6% YoY due to positive development in international markets.

Negative Factors

Earnings Outlook

The outlook on revenue and earnings sits below consensus with expected low single-digit revisions.

EBITDA Margin

Group adj. EBITDA is down -8% YoY to €81.3m, translating into a margin 26.9% (PY 29.7%).

Revenue Growth

The new fiscal year guidance appears conservative with only flat revenue growth projected.

Dermapharm Holding SE Business Overview & Revenue Model

Company Description

Dermapharm Holding SE is a pharmaceutical company based in Germany, specializing in the development, production, and commercialization of branded pharmaceuticals and other healthcare products. The company's core operations are in the pharmaceutical and healthcare sectors, with a product portfolio that includes dermatologicals, allergy treatments, vitamins, and dietary supplements. Dermapharm also engages in the production of medical devices and cosmetics, serving both domestic and international markets.

How the Company Makes Money

Dermapharm Holding SE generates revenue primarily through the sale of its pharmaceutical and healthcare products. The company's revenue model is centered around the development and commercialization of branded pharmaceuticals, which are sold to pharmacies, healthcare providers, and directly to consumers. Key revenue streams include sales of dermatological products, allergy treatments, and vitamins. Additionally, Dermapharm benefits from strategic partnerships and acquisitions that expand its product offerings and market reach. The company leverages its strong research and development capabilities to continuously innovate and introduce new products, which contributes to its earnings growth. International expansion and distribution agreements also play a significant role in increasing the company's revenue.

Dermapharm Holding SE Financial Statement Overview

Summary

Dermapharm Holding SE presents a strong financial position with consistent revenue growth and solid operational performance. The company demonstrates effective cost management with a robust gross profit margin, although net profit margin fluctuations indicate some volatility. The balance sheet reflects stable equity growth, but increased debt reliance could pose risks. Positive operating and free cash flows highlight the ability to support future investments and debt repayments.

Income Statement

Dermapharm Holding SE has shown strong revenue growth over the years, with a notable increase from €700.9M in 2019 to €1.18B in 2024. The gross profit margin remains robust, indicating effective cost management. However, the net profit margin shows fluctuations, indicating some volatility in converting revenue into net income. Despite this, EBIT and EBITDA margins are healthy, signifying strong operational performance.

Balance Sheet

The balance sheet reflects a stable equity position with a growing stockholders' equity over the years, from €278.6M in 2019 to €604.4M in 2024. The debt-to-equity ratio indicates an increased reliance on debt, which could pose risks if not managed prudently. However, the equity ratio stands firm, demonstrating a balanced asset financing structure.

Cash Flow

Operating cash flow has been consistently positive, showing the company's ability to generate cash from operations. Free cash flow has also grown, supporting future investments and debt repayments. The free cash flow to net income ratio highlights efficient cash conversion, although some volatility is present in annual cash flows due to varying capital expenditures.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.18B	1.14B	1.02B	942.91M	793.83M
Gross Profit	767.07M	719.16M	660.83M	620.69M	463.48M
EBITDA	320.91M	265.55M	329.81M	358.10M	186.57M
Net Income	113.79M	62.37M	134.24M	209.58M	85.83M
Balance Sheet
Total Assets	2.08B	2.16B	1.41B	1.41B	1.22B
Cash, Cash Equivalents and Short-Term Investments	121.71M	159.54M	161.36M	172.06M	121.66M
Total Debt	979.61M	1.08B	516.45M	580.30M	606.80M
Total Liabilities	1.47B	1.62B	880.34M	907.13M	899.81M
Stockholders Equity	604.42M	539.21M	531.59M	497.32M	321.97M
Cash Flow
Free Cash Flow	163.14M	177.88M	249.52M	189.16M	90.30M
Operating Cash Flow	201.38M	219.42M	288.53M	250.37M	131.10M
Investing Cash Flow	-29.61M	-415.43M	-99.01M	-129.35M	-105.91M
Financing Cash Flow	-209.17M	204.54M	-199.77M	-80.98M	-14.09M

Dermapharm Holding SE Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 35.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DMP, the sentiment is Neutral. The current price of 35.2 is above the 20-day moving average (MA) of 34.39, below the 50-day MA of 35.35, and below the 200-day MA of 35.74, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 55.90 is Neutral, neither overbought nor oversold. The STOCH value of 91.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:DMP.

Dermapharm Holding SE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PSG	78 Outperform	€338.40M	16.83	48.46%	1.81%	13.80%	10.94%
PSG	78 Outperform	€338.40M	16.83	48.46%	1.81%	13.80%	10.94%
ILM1	75 Outperform	$322.90M	21.46	2.99%	―	5.62%	-21.87%
DMP	70 Outperform	€1.90B	18.30	16.97%	2.56%	6.24%	83.05%
Sector *	64 Neutral	€7.32B	20.80	1.45%	1.93%	1.18%	-29.88%
APPH	58 Neutral	€92.23M	119.89	2.46%	―	31.12%	―